Dec 20, 2024
Applied Therapeutics Appoints John H. Johnson as Executive Chairman
Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare
Nov 07, 2024
Applied Therapeutics Reports Third Quarter 2024 Financial Results
- NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in Q1 2025 - NDA submission for govorestat for the treatment of SORD Deficiency under Accelerated Approval expected
Nov 05, 2024
Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present at the
Sep 04, 2024
Applied Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the company will
Aug 07, 2024
Applied Therapeutics Reports Second Quarter 2024 Financial Results
NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in early Q1 2025 FDA Genetic Metabolic Diseases Advisory Committee (GeMDAC) Meeting to discuss NDA for govorestat for
Jul 01, 2024
Applied Therapeutics Added to Russell 3000® Index
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company was added
May 09, 2024
Applied Therapeutics Reports First Quarter 2024 Financial Results
Govorestat NDA for Classic Galactosemia under Priority Review, PDUFA target action date of November 28, 2024 Govorestat MAA under review by EMA; Day 120 3-month clock-stop extension granted; decision expected in early Q1 2025 Company discussing potential NDA submission under Accelerated Approval
Displaying 1 - 10 of 19


Print Page
Print Page
Email Alerts
RSS Feeds
RSS Feeds
Contact IR
Contact IR
AP_logo_KO
linkedin
facebook
twitter

©2024 Applied Therapeutics All Rights Reserved

linkedin
facebook
twitter
AP_logo_KO

©2024 Applied Therapeutics All Rights Reserved